Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 25Multiple Myeloma 24Leukemia, Myeloid, Acute 21Recurrence 20Colorectal Neoplasms 17Neoplasm Metastasis 17Lymphoma, Non-Hodgkin 15Ovarian Neoplasms 15Carcinoma, Renal Cell 14Leukemia 14Leukemia, Lymphocytic, Chronic, B-Cell 14Melanoma 14Lymphoma, Follicular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lung Neoplasms 11Myelodysplastic Syndromes 11Urinary Bladder Neoplasms 11Carcinoma, Hepatocellular 10Hematologic Neoplasms 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Adenocarcinoma 9Glioma 9Lymphoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Mantle-Cell 9Prostatic Neoplasms 9Stomach Neoplasms 9

Interventions

pembrolizumab 1Melphalan 1Ipilimumab 1Dacarbazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Uveal Melanoma × Clear all
NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Immunocore Ltd

Phase 2 Completed
378 enrolled 15 charts 1 FDA
Dermatologic

Uveal Melanoma, Melanoma

NCT02678572 2023-12-21

FOCUS

Delcath Systems Inc.

Phase 3 Completed
102 enrolled 1 FDA
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡